Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > oXiris and PMX

<< Previous

Bullboard Posts

Next >>

Comment by mercedesmanon Jul 19, 2024 8:11am

166 Views

Post# 36139662

RE:RE:oXiris and PMX

Right G !

Whomever owns both worldwide will have a great one-two punch for cases of ESS, from mild to severe cases, guided by the EAA ( personalized care)

Of course, in the US, it looks like PMX/EAA will be the only option for the foreseeable ( assuming FDA approval)

Not even outlier competitors like Cytosorbents can penetrate the market there.

MM

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario